Synmosa Biopharma (ROCO:4114) Total Liabilities : NT$3,905 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Total Liabilities?

Synmosa Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 was NT$3,905 Mil.

Synmosa Biopharma's quarterly Total Liabilities increased from Jun. 2024 (NT$3,852.41 Mil) to Sep. 2024 (NT$3,853.42 Mil) and increased from Sep. 2024 (NT$3,853.42 Mil) to Dec. 2024 (NT$3,905.27 Mil).

Synmosa Biopharma's annual Total Liabilities declined from Dec. 2022 (NT$4,553.70 Mil) to Dec. 2023 (NT$3,627.68 Mil) but then increased from Dec. 2023 (NT$3,627.68 Mil) to Dec. 2024 (NT$3,905.27 Mil).

Synmosa Biopharma Total Liabilities Historical Data

The historical data trend for Synmosa Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma Total Liabilities Chart

Synmosa Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

4,422.85

4,221.42

4,553.70

3,627.68

3,905.27

Synmosa Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															3,627.68	3,950.14	3,852.41	3,853.42	3,905.27

Synmosa Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Synmosa Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2074.588	+	(1778.661	+	44.215
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	7.803	+	0)
	=	3,905

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	12304.141	-	8398.874
	=	3,905

Synmosa Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2074.588	+	(1778.661	+	44.215
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	7.803	+	0)
	=	3,905

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	12304.141	-	8398.874
	=	3,905

Synmosa Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines